293 results on '"Lips, Esther H."'
Search Results
2. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
3. PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
4. Immune landscape of breast tumors with low and intermediate estrogen receptor expression
5. Predicting treatment outcome using kinome activity profiling in HER2+ breast cancer biopsies
6. DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS
7. Tumour-educated platelets for breast cancer detection: biological and technical insights
8. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
9. Learning to distinguish progressive and non-progressive ductal carcinoma in situ
10. Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials
11. Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer
12. Archival single-cell genomics reveals persistent subclones during DCIS progression
13. Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights
14. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
15. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests
16. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
17. Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature
18. Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance
19. Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.
20. Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ
21. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
22. Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ
23. The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review
24. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study
25. Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
26. Avoiding Overtreatment of Ductal Carcinoma in situ
27. Ductal carcinoma in situ: to treat or not to treat, that is the question
28. Microcalcification crystallography as a potential marker of DCIS recurrence
29. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
30. Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer
31. Abstract 125: Archival single cell sequencing reveals persistent subclones over years to decades of DCIS progression
32. Supplementary table 2 from BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
33. Supplementary Table from Progression and Tumor Heterogeneity Analysis in Early Rectal Cancer
34. Supplementary Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
35. Supplementary table 1 from BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
36. Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
37. Supplementary Materials and Methods from Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study
38. Data from Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer
39. Supplemental Table S1 from Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer
40. Supplemental Figures 1 - 4 from Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer
41. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)
42. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
43. Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
44. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
45. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS
46. Abstract PR006: A living biobank of patient-derived ductal carcinoma in situ (DCIS) Mouse-INtraDuctal (MIND) xenografts identifies multiple risk factors of invasive progression
47. Abstract PR002: Genomic predictor can discriminate between high- and low-risk DCIS
48. Abstract A016: Identification of methylated regions in ductal carcinoma in situ and association with disease progression
49. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
50. Microcalcification crystallography as a potential marker of DCIS recurrence.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.